We are live on !
Find out more
ACT Capital Management Portfolio holdings
AUM
$153M
Turnover
44.74%
This Fund
S&P 500
This Quarter Est. Return
+24.15%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$25.8M
(+20%)
Cap. Flow
+$5.34M
Cap. Flow % of AUM
Cap. Flow %
3.49%
Top 10 Holdings %
Top 10 Hldgs %
66%
Holding
76
New
20
Increased
15
Reduced
12
Closed
14
Avg Time Held
0.8
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$4.3M |
| 2 |
AST SpaceMobile
ASTS
|
+$3.79M |
| 3 |
Abivax
ABVX
|
+$2.95M |
| 4 |
Palvella Therapeutics
PVLA
|
+$2.73M |
| 5 |
Arrowhead Research
ARWR
|
+$2.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$5.05M |
| 2 |
Krystal Biotech
KRYS
|
+$4.62M |
| 3 |
Celcuity
CELC
|
+$3.41M |
| 4 |
Applied Optoelectronics
AAOI
|
+$3.23M |
| 5 |
Alumis Inc
ALMS
|
+$2.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.9% |
| 2 | Energy | 17.83% |
| 3 | Technology | 7.89% |
| 4 | Consumer Discretionary | 4.98% |
| 5 | Industrials | 1.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$9.2B
| $16.7M | 10.93% |
45,000
-15,477
| -26% | -$4.62M |
2021 Q2
20 quarters
|
|
2
TG Therapeutics
TGTX
$9.43B
| $13.8M | 9.01% |
251,025
+2,000
| +0.8% | +$81.9K |
2025 Q4
2 quarters
|
|
|
3
Abivax
ABVX
$7.83B
| $12.9M | 8.45% |
97,000
+26,100
| +37% | +$2.95M |
2025 Q4
2 quarters
|
|
4
Chevron
CVX
$423B
| $12.4M | 8.12% |
75,000
| – | – |
2021 Q3
19 quarters
|
|
5
ExxonMobil
XOM
$690B
| $10.7M | 7.01% |
78,500
+8,500
| +12% | +$1.27M |
2022 Q2
16 quarters
|
|
|
6
Arrowhead Research
ARWR
$8.71B
| $8.97M | 5.86% |
110,100
+27,600
| +33% | +$2.04M |
2021 Q2
20 quarters
|
|
7
Viking Therapeutics
VKTX
$3.57B
| $8.16M | 5.33% |
209,300
| – | – |
2025 Q4
2 quarters
|
|
|
8
Celcuity
CELC
$3.39B
| $6.5M | 4.25% |
62,150
-29,525
| -32% | -$3.41M |
2025 Q4
2 quarters
|
|
9
Nektar Therapeutics
NKTR
$1.31B
| $6.23M | 4.07% |
89,300
+18,400
| +26% | +$1.35M |
2025 Q4
2 quarters
|
|
|
10
Tesla
TSLA
$1.52T
| $4.54M | 2.97% |
+10,800
| New | +$4.3M |
2026 Q2
0 quarters
|
|
11
Cytokinetics
CYTK
$8.84B
| $4.05M | 2.64% |
47,500
-17,000
| -26% | -$1.22M |
2025 Q4
2 quarters
|
|
|
12
AST SpaceMobile
ASTS
$10.7B
| $3.87M | 2.53% |
+43,500
| New | +$3.79M |
2026 Q2
0 quarters
|
|
|
13
Palvella Therapeutics
PVLA
$2.34B
| $3.44M | 2.25% |
+22,500
| New | +$2.73M |
2026 Q2
0 quarters
|
|
|
14
Amazon
AMZN
$2.88T
| $3.07M | 2.01% |
12,900
-20,100
| -61% | -$5.05M |
2025 Q4
2 quarters
|
|
15
Nuvation Bio
NUVB
$1.66B
| $2.95M | 1.93% |
520,000
+230,000
| +79% | +$1.12M |
2025 Q4
2 quarters
|
|
16
Xenon Pharmaceuticals
XENE
$3.8B
| $2.9M | 1.89% |
48,000
+14,500
| +43% | +$805K |
2026 Q1
1 quarter
|
|
17
Energy Transfer Partners
ET
$67B
| $2.54M | 1.66% |
133,100
| – | – |
2022 Q2
16 quarters
|
|
18
Bloom Energy
BE
$59.2B
| $2.27M | 1.48% |
7,500
+3,000
| +67% | +$769K |
2025 Q4
2 quarters
|
|
19
Freeport-McMoran
FCX
$89.9B
| $2.04M | 1.34% |
32,500
-6,000
| -16% | -$386K |
2026 Q1
1 quarter
|
|
20
Nebius Group N.V.
NBIS
$38.5B
| $1.88M | 1.23% |
+6,800
| New | +$1.35M |
2026 Q2
0 quarters
|
|
|
21
Alumis Inc
ALMS
$848M
| $1.45M | 0.95% |
51,600
-122,650
| -70% | -$2.85M |
2026 Q1
1 quarter
|
|
22
Ambarella
AMBA
$2.69B
| $1.37M | 0.9% |
+16,000
| New | +$1.1M |
2026 Q2
0 quarters
|
|
23
Cerebras Systems
CBRS
$21.8B
| $1.24M | 0.81% |
+5,600
| New | +$1.32M |
2026 Q2
0 quarters
|
|
24
Definium Therapeutics
DFTX
$4.39B
| $1.18M | 0.77% |
+25,000
| New | +$618K |
2026 Q2
0 quarters
|
|
25
Nokia
NOK
$46.2B
| $1.09M | 0.71% |
+82,000
| New | +$1.06M |
2026 Q2
0 quarters
|
|
Similar funds
TL
ACT Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, ACT Capital Management held 76 positions worth $153M, up 20% from $127M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
ACT Capital Management deployed $5.34M of net new capital in Q2 2026, opening 20 new positions and adding to 15 existing holdings. Its largest new stake was Tesla: 10,800 shares worth $4.54M.
By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 62% a quarter earlier, followed by Energy and Technology.
On the sell side, the largest reduction was Amazon, an estimated $5.05M trimmed.
- ACT Capital Management's largest Q2 2026 buy was Tesla: 10,800 shares worth $4.54M.
- ACT Capital Management added most to Abivax in Q2 2026, an estimated $2.95M increase.
- ACT Capital Management's biggest Q2 2026 reduction was Amazon, cutting an estimated $5.05M.
- ACT Capital Management fully exited STAAR Surgical in Q2 2026, selling an estimated $1.04M.
- ACT Capital Management's ten largest holdings make up 66% of its $153M portfolio in Q2 2026.
- ACT Capital Management opened 20 new positions and closed 14 in Q2 2026.
- ACT Capital Management's portfolio value rose 20% quarter-over-quarter to $153M.
Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.